AlphAIAlphAI — Financial news for AI agents
investing.comSEP 302 min read$CNXC

Concentrix earnings analysis: questions answered and next catalysts

Concentrix Corp (CNXC) reported Q3 earnings with a $0.21 EPS beat ($2.92) but a $30M revenue miss ($2.45B vs. $2.48B est). Shares initially dropped 9.77% before recovering 3.12%. Management highlighted AI-driven revenue growth (50% of total) and cash flow strength ($218M), but revenue declines due to specific client exits and offshoring. The dividend was raised to $0.37/share. Growth is expected to return in 2028, with key catalysts including Q4 earnings and debt paydown milestones.

Original reporting
investing.com
Published Sep 30, 2026, 7:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 7:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CNXC
Neutral
high confidence
Mentioned
$CNXC
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CNXCNeutralHigh
01

Why it matters

The earnings beat and dividend hike provide immediate upside catalysts, while the revenue miss and hyperscaler exits create downside risk, leading to heightened volatility.

02

Market read

The report offers fresh guidance and dividend news that can drive short‑term price action and influence sector sentiment toward AI‑enabled BPO firms.

03

What to watch

Offshoring headwinds are capped; the dividend raise may attract income‑focused investors, supporting price stability.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Concentrix Corp (CNXC) reported Q3 2026 results, showing profitability improvements but a slight revenue shortfall, and announced a higher dividend.

Company-level read

Ticker impact

$CNXCNeutralHigh confidence
Context

Q3 earnings release with EPS beat, revenue miss, dividend increase and guidance updates.

Expected impact

likely pressure as market prices in revenue miss and dividend raise, with upside potential if FY2027 guidance holds.

Evidence & confidence

The earnings beat and dividend hike provide a concrete catalyst; the revenue shortfall and hyperscaler exits create downside risk, making the stock sensitive to near‑term trading.

Market effects

Sector

Highlights pressure on BPO and outsourcing sector from hyperscaler pull‑backs while showcasing AI‑driven margin expansion.

Regional

U.S. tech and services investors may adjust exposure to AI‑enabled BPO firms.

Global

Signals broader AI adoption trends and potential re‑rating of similar service providers worldwide.

Counterpoint

What could challenge this read

If the AI‑driven revenue mix accelerates faster than guidance, the stock could rally despite short‑term revenue miss.

Key entities

  • Executive
    Chris Caldwell

    CEO who discussed AI pivot and dividend increase.

  • Executive
    Andre Valentine

    CFO who commented on free cash flow and debt reduction.

Read at source← All news

Related articles

SEP 30
$CNXCMedAI 8/10

Why Concentrix Stock Ended Up Moving Higher Today

Concentrix (CNXC) reported fiscal Q3 revenue below estimates due to client shifts, but earnings beat expectations. CEO Christopher Caldwell attributed the shortfall to client preferences, not customer loss. The stock initially dropped but recovered, up 3% by midday. Analysts' average price target is $33.50, over 30% above current levels.

aol.com3 min
SEP 30
$LQDAMed

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

cnbc.com2 min
SEP 30
$CNXCLow

Why Concentrix (CNXC) Stock Is Up Today

Concentrix (CNXC) stock rose 4% after reporting a Q3 net loss of $988.1M, driven by a $1.5B goodwill impairment charge. Revenue fell 1.2% YoY to $2.45B, missing estimates. Adjusted EPS was $2.92. The company cited AI deployments and client decisions for the decline. Shares later cooled to $25.73, up 1%.

stockstory.org2 min
SEP 30
$CNXCHighAI 8/10

Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s

Concentrix Corp (NASDAQ:CNXC) shares fell 10.6% premarket after reporting mixed Q3 results, missing sales estimates and issuing weak Q4 guidance. The company also narrowed its FY26 adjusted EPS guidance and cut FY26 sales guidance below estimates. Earnings of $2.92 per share beat estimates, while sales of $2.454 billion missed expectations.

benzinga.com2 min
SEP 30
$BAMed

Stocks making the biggest moves premarket: Robinhood, Boeing, Moderna & more

Boeing shares rose 2% after securing a $20B defense contract. Robinhood gained 2% with new AI features and 24/7 trading plans. Concentrix dropped 9.5% on weak earnings and guidance. Moderna fell 6% after a Citi downgrade. FormFactor rose 1% on a Deutsche Bank buy rating. Cal-Maine Foods declined 6.5% on larger-than-expected losses.

cnbc.com2 min
SEP 30
$CNXCHighAI 8/10

Concentrix (CNXC) Q3 2026 Earnings Call Transcript

Concentrix (CNXC) reported Q3 2026 revenue of $2.45B, down 1.2%, with non-GAAP EPS at $2.92, up $0.14 YoY. Non-GAAP operating income exceeded guidance, but GAAP net loss was $988.1M due to a $1.05B goodwill impairment charge. Q4 revenue guidance is $2.41B-$2.46B, with FY 2026 revenue expected at $9.827B-$9.877B. Management highlighted AI-driven growth and debt reduction plans.

fool.com3 min